Statin effect on Lp(a) and management strategies

Short answer: statins don't reliably raise Lp(a); they mainly lower LDL (the key driver of risk). In some people, Lp(a) may appear 10–20% higher on a statin, but this is inconsistent, small, and not a reason to stop a statin when indicated—because event reduction from LDL lowering is clear. What to do about Lp(a): 1) Measure it once in adulthood (mg/dL or nmol/L; high ≈ >50 mg/dL or >125 nmol/L). 2) If elevated, focus on lowering overall risk: push LDL/non‑HDL lower (often to LDL <55–70 mg/dL), control BP, A1c, weight, and don't smoke. 3) Therapies that lower Lp(a): PCSK9 inhibitors cut Lp(a) ~20–30% and reduce events; niacin lowers Lp(a) but hasn't improved outcomes and has side effects, so not recommended. 4) Dedicated Lp(a)‑lowering drugs (antisense/siRNA like pelacarsen, olpasiran) are in late trials; not yet approved.

Note: In the Phase 3 Lp(a)HORIZON trial (8,000+ high-risk patients), pelacarsen successfully lowered Lp(a) but did not significantly reduce major cardiovascular events (heart attack, stroke, cardiovascular death) versus placebo. This does not disprove the Lp(a) hypothesis — genetic and epidemiologic evidence still strongly supports high Lp(a) as a causal risk factor — it just means this particular drug didn't demonstrate a benefit. Other agents (olpasiran, lepodisiran) lower Lp(a) by ~90%+ and their outcomes trials are still pending. Bottom line: if your Lp(a) is high, keep aggressively managing LDL (target range in the 50s) and discuss with your doctor — this remains especially relevant for South Asians.